Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well temsirolimus works in treating patients with
recurrent or persistent cancer of the uterus. Temsirolimus may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth.